

MAP Pharmaceuticals, Inc.  
Form 8-K  
October 04, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 4, 2010**

**MAP PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**001-33719**  
**(Commission**

**20-0507047**  
**(IRS Employer**

**of Incorporation)**

**File Number)**

**Identification No.)**

**2400 Bayshore Parkway, Suite 200, Mountain View, CA**  
**(Address of Principal Executive Offices)**

**94043**  
**(Zip Code)**

**Registrant's telephone number, including area code: (650) 386-3100**

**(Former Name or Former Address, if Changed Since Last Report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 8-K

- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On October 4, 2010, MAP Pharmaceuticals, Inc. (the Company ) issued a press release announcing the closing of the underwritten registered offering of 3,450,000 shares of its common stock, including 450,000 shares of its common stock issued pursuant to the full exercise of the over-allotment option granted to the underwriters in the offering, at an offering price of \$14.50 per share. The Company expects the net proceeds from the offering, including the exercise of the over-allotment option, to be approximately \$47.1 million, after underwriting discounts and commissions and estimated offering expenses. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| 99.1               | Press Release of MAP Pharmaceuticals, Inc., dated October 4, 2010. |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 4, 2010

**MAP PHARMACEUTICALS, INC.**

By: /s/ CHARLENE A. FRIEDMAN  
Name: **Charlene A. Friedman**  
Title: **Vice President, General Counsel and Secretary**

**INDEX TO EXHIBITS FILED WITH  
THE CURRENT REPORT ON FORM 8-K**

| <b>Exhibit</b> | <b>Description</b>   |
|----------------|--|
| 99.1           | Press Release of MAP Pharmaceuticals, Inc., dated October 4, 2010. |